Affluent Medical SA

Paris Stock Exchange AFME.PA

Affluent Medical SA Price to Sales Ratio (P/S) on January 14, 2025: 41.23

Affluent Medical SA Price to Sales Ratio (P/S) is 41.23 on January 14, 2025, a -18.47% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Affluent Medical SA 52-week high Price to Sales Ratio (P/S) is 60.98 on March 13, 2024, which is 47.90% above the current Price to Sales Ratio (P/S).
Affluent Medical SA 52-week low Price to Sales Ratio (P/S) is 36.68 on December 03, 2024, which is -11.04% below the current Price to Sales Ratio (P/S).
Affluent Medical SA average Price to Sales Ratio (P/S) for the last 52 weeks is 51.05.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Paris Stock Exchange: AFME.PA

Affluent Medical SA

CEO	Sebastien Ladet Ph.D.
IPO Date	June 14, 2021
Location	France
Headquarters	320, avenue Archimède
Employees	66
Sector	Health Care
Industries Medical Instruments Biotechnology Pharmaceuticals

Description

Affluent Medical SA develops minimally invasive medical devices for the treatment of heart and vascular diseases in France. It develops Kardiozis technology for the treatment of abdominal aortic aneurysm; Kalios and Epygon implants to treat mitral insufficiency; and Artus implant, an implantable electro-mechanical artificial sphincter for the treatment of severe urinary incontinence in women and men. The company was founded in 2011 and is based in Aix-en-Provence, France.

Key trends

Past 5 years